Mucus-permeable polymyxin B-hyaluronic acid/ poly (lactic-co-glycolic acid) nanoparticle platform for the nebulized treatment of lung infections
Copyright © 2022 Elsevier Inc. All rights reserved..
The aim of this study was to improve the bioavailability of polymyxin B (PMB) in pulmonary nebulized drug delivery. To this end, we developed a nano-delivery system that penetrates the mucus barrier of the lung. Hydrophilic hyaluronic acid (HA) was combined with a water-in-oil system containing a poly (lactic acid)-glycolic acid copolymer of PMB to prepare HAPLGA-PMB nanoparticles (NPs) with good surface properties. HA@PLGA-PMB NPs with suitable electrical properties, particle size, and good hydrophilicity prevented strong interactions between the NPs and mucus, thereby allowing more drugs to enter deeper into the lung. Compared to the free drug PMB, NPs had more than 2-fold higher mucus penetration efficiency in vitro and better delivery to infected alveolar cells during in vivo nebulization. NPs had better biocompatibility, which further reduced the drug toxicity. More importantly, NPs showed better antimicrobial therapeutic efficacy in the treatment of lung infections in mice. These findings may provide support for the clinical application of nebulized pulmonary antibiotics.
| Errataetall: |
ErratumIn: J Colloid Interface Sci. 2023 Jan;629(Pt A):882-883. - PMID 36150265 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:624 |
|---|---|
| Enthalten in: |
Journal of colloid and interface science - 624(2022) vom: 15. Okt., Seite 307-319 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wu, Jun [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.06.2022 Date Revised 23.09.2022 published: Print-Electronic ErratumIn: J Colloid Interface Sci. 2023 Jan;629(Pt A):882-883. - PMID 36150265 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jcis.2022.05.121 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341828041 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341828041 | ||
| 003 | DE-627 | ||
| 005 | 20231226012654.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcis.2022.05.121 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1139.xml |
| 035 | |a (DE-627)NLM341828041 | ||
| 035 | |a (NLM)35660900 | ||
| 035 | |a (PII)S0021-9797(22)00905-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wu, Jun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mucus-permeable polymyxin B-hyaluronic acid/ poly (lactic-co-glycolic acid) nanoparticle platform for the nebulized treatment of lung infections |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.06.2022 | ||
| 500 | |a Date Revised 23.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: J Colloid Interface Sci. 2023 Jan;629(Pt A):882-883. - PMID 36150265 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a The aim of this study was to improve the bioavailability of polymyxin B (PMB) in pulmonary nebulized drug delivery. To this end, we developed a nano-delivery system that penetrates the mucus barrier of the lung. Hydrophilic hyaluronic acid (HA) was combined with a water-in-oil system containing a poly (lactic acid)-glycolic acid copolymer of PMB to prepare HAPLGA-PMB nanoparticles (NPs) with good surface properties. HA@PLGA-PMB NPs with suitable electrical properties, particle size, and good hydrophilicity prevented strong interactions between the NPs and mucus, thereby allowing more drugs to enter deeper into the lung. Compared to the free drug PMB, NPs had more than 2-fold higher mucus penetration efficiency in vitro and better delivery to infected alveolar cells during in vivo nebulization. NPs had better biocompatibility, which further reduced the drug toxicity. More importantly, NPs showed better antimicrobial therapeutic efficacy in the treatment of lung infections in mice. These findings may provide support for the clinical application of nebulized pulmonary antibiotics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Hydrophilic | |
| 650 | 4 | |a Mucus barrier | |
| 650 | 4 | |a Mucus permeability | |
| 650 | 4 | |a Sodium hyaluronate | |
| 650 | 4 | |a polymyxin B | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Glycolates |2 NLM | |
| 650 | 7 | |a glycolic acid |2 NLM | |
| 650 | 7 | |a 0WT12SX38S |2 NLM | |
| 650 | 7 | |a Polylactic Acid-Polyglycolic Acid Copolymer |2 NLM | |
| 650 | 7 | |a 1SIA8062RS |2 NLM | |
| 650 | 7 | |a Polyglycolic Acid |2 NLM | |
| 650 | 7 | |a 26009-03-0 |2 NLM | |
| 650 | 7 | |a Lactic Acid |2 NLM | |
| 650 | 7 | |a 33X04XA5AT |2 NLM | |
| 650 | 7 | |a Hyaluronic Acid |2 NLM | |
| 650 | 7 | |a 9004-61-9 |2 NLM | |
| 650 | 7 | |a Polymyxin B |2 NLM | |
| 650 | 7 | |a J2VZ07J96K |2 NLM | |
| 700 | 1 | |a Zhai, Tianshu |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Qingsong |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Yicheng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Runwei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Ouyang, Qiuhong |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Tiantian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhan, Qingyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Fang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of colloid and interface science |d 1966 |g 624(2022) vom: 15. Okt., Seite 307-319 |w (DE-627)NLM041487958 |x 1095-7103 |7 nnns |
| 773 | 1 | 8 | |g volume:624 |g year:2022 |g day:15 |g month:10 |g pages:307-319 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcis.2022.05.121 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 624 |j 2022 |b 15 |c 10 |h 307-319 | ||